1. Home
  2. IMRN vs PT Comparison

IMRN vs PT Comparison

Compare IMRN & PT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • PT
  • Stock Information
  • Founded
  • IMRN 1994
  • PT 2012
  • Country
  • IMRN Australia
  • PT China
  • Employees
  • IMRN N/A
  • PT N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • PT Computer Software: Programming Data Processing
  • Sector
  • IMRN Health Care
  • PT Technology
  • Exchange
  • IMRN Nasdaq
  • PT Nasdaq
  • Market Cap
  • IMRN 14.4M
  • PT 14.7M
  • IPO Year
  • IMRN N/A
  • PT 2018
  • Fundamental
  • Price
  • IMRN $2.10
  • PT $0.98
  • Analyst Decision
  • IMRN
  • PT
  • Analyst Count
  • IMRN 0
  • PT 0
  • Target Price
  • IMRN N/A
  • PT N/A
  • AVG Volume (30 Days)
  • IMRN 96.3K
  • PT 120.8K
  • Earning Date
  • IMRN 08-29-2025
  • PT 09-19-2025
  • Dividend Yield
  • IMRN N/A
  • PT N/A
  • EPS Growth
  • IMRN N/A
  • PT N/A
  • EPS
  • IMRN N/A
  • PT N/A
  • Revenue
  • IMRN $4,777,422.00
  • PT $4,961,892.00
  • Revenue This Year
  • IMRN N/A
  • PT N/A
  • Revenue Next Year
  • IMRN N/A
  • PT N/A
  • P/E Ratio
  • IMRN N/A
  • PT N/A
  • Revenue Growth
  • IMRN 48.63
  • PT 9.20
  • 52 Week Low
  • IMRN $1.50
  • PT $0.76
  • 52 Week High
  • IMRN $2.48
  • PT $1.38
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 50.56
  • PT 59.15
  • Support Level
  • IMRN $2.10
  • PT $0.93
  • Resistance Level
  • IMRN $2.24
  • PT $1.00
  • Average True Range (ATR)
  • IMRN 0.12
  • PT 0.06
  • MACD
  • IMRN -0.02
  • PT 0.01
  • Stochastic Oscillator
  • IMRN 32.50
  • PT 94.01

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.

Share on Social Networks: